SCHEMBL6769256

SCHEMBL6769256

CC(CC=O)c1cc(-c2cccc([N+](=O)[O-])c2)no1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.47
NPC1 O15118 4/20 0.46
RAB9A P51151 4/20 0.46
MAPT P10636 7/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
MAPK1 P28482 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
GRM5 P41594 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
CA12 O43570 1/20 0.43
CA9 Q16790 1/20 0.43
IDO1 P14902 1/20 0.42
CHRNB2 P17787 1/20 0.42
CHRNA5 P30532 1/20 0.42
CHRNA4 P43681 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6769163 0.81 RAB9A (0.46) ALDH1A1NPC1RAB9AMAPTSMN1; SMN2
SCHEMBL6774258 0.76 SMN1; SMN2 (0.40) ALDH1A1NPC1RAB9AMAPTSMN1; SMN2
SCHEMBL6768362 0.76 DRD2 (0.55) ALDH1A1NPC1RAB9AMAPTSMN1; SMN2
SCHEMBL20501822 0.75 RAB9A (0.56) ALDH1A1NPC1RAB9AMAPTSMN1; SMN2
SCHEMBL21200200 0.74 KMT2A (0.55) ALDH1A1MAPTSMN1; SMN2L3MBTL1MEN1
SCHEMBL21200199 0.74 KMT2A (0.55) ALDH1A1MAPTSMN1; SMN2L3MBTL1MEN1
SCHEMBL6767117 0.73 MAPT (0.43) ALDH1A1NPC1RAB9AMAPTSMN1; SMN2
SCHEMBL22348262 0.72 NPC1 (0.56) ALDH1A1NPC1RAB9AMAPTSMN1; SMN2
SCHEMBL27544629 0.72 NPC1 (0.56) ALDH1A1NPC1RAB9AMAPTSMN1; SMN2
SCHEMBL22348509 0.72 NPC1 (0.52) ALDH1A1NPC1RAB9AMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6723724-B2 PSYCHOLOGICAL DISORDERS KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2004-04-20 US disclosed
US-20020119983-A1 Novel isoxazolylalkylpiperazine derivatives having selective biological activity at dopamine D3 or D4 receptor, and preparation thereof KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2002-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020119983-A1 Novel isoxazolylalkylpiperazine derivatives having selective biological activity at dopamine D3 or D4 receptor, and preparation thereof DRD4, DRD3, DRD2 ALDH1A1 429/4885NPC1 4523/4885RAB9A 1831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.